NeOnc Aims to Clarify NEO212 Path Forward in Key FDA Meeting

Event summary

NeOnc scheduled an End-of-Phase 1 Type B meeting with the FDA for November 17, 2026 to discuss NEO212's development path.
NEO212's Phase 1 dose escalation reached 810 mg, with a recommended Phase 2 dose of 610 mg.
Early signals show tumor reduction in glioblastoma patient and stable disease in lung cancer patient with brain metastases.
Roth Capital initiated coverage with a $20 price target, anticipating potential pivotal-trial starts by year-end.

The big picture

NeOnc is positioning itself as a key player in CNS cancer therapeutics, with two potential therapies advancing in parallel. The November FDA meeting could be a pivotal moment in defining NEO212's development trajectory, while the broader pipeline attracts institutional investor attention. The company's ability to secure regulatory clarity and maintain clinical momentum will be critical in sustaining its upward valuation trajectory.

What we're watching

Regulatory Clarity: Whether the FDA provides a workable path forward for NEO212's population, endpoints, and study design.
Clinical Momentum: The pace at which NeOnc can transition NEO212 from dose-finding to late-stage development.
Investor Sentiment: How Wall Street reacts to potential pivotal-trial starts for both NEO212 and NEO100 by year-end.